Table 2. Comparative analysis between patients with and without history of frequent infections, with or without malignancy, and with or without histologically confirmed rejection.
| Number of samples (%) | TTVL (copies/mL) (median (IQR), range) | TTVL (log10 copies/mL) (mean ± SD) | p-value between TTVL (log10 copies/mL) | QFM (IU/mL) (median (IQR), range) | QFM (log10 IU/mL) |
p-value between QFM (log10 IU/mL) | |
|---|---|---|---|---|---|---|---|
| Frequent infections | 128 (100%) |
||||||
| Yes | 69 (53.9%) | 15,060 (IQR: 3,000 – 139,000), range 0 – 2.63 ×109 | 4.17±1.87 | p = 0.278 | 81.4 (IQR: 21.65 – 261.5), range 0.31 – 1,000 | 1.70 ± 1.78 | p = 0.588 |
| No | 59 (46.1%) | 6,240 (IQR: 2,256 – 139,000), range 0 – 2.61 ×108 | 3.77±2.33 | 80.8 (IQR: 11.5 – 200), range 0.76 – 955 | 1.70 ± 0.80 | ||
| Malignant disease | 128 (100%) | ||||||
| Yes | 19 (14.8%) | 8,100 (IQR: 0-34,200), range 0 – 11,300.000 | 3.09±2.31 | p = 0.041* | 116.7 (IQR: 77.03-544), range 0.48 – 955.0 | 2.02 ± 0.87 | p = 0.112 |
| No | 109 (85.2%) | 11,400 (IQR: 3,000 – 144,500), range 0 – 2.63 ×109 | 4.15±2.02 | 64.7 (IQR: 17.55 – 200.3), range 0.31 – 1,000 | 1.69 ± 0.79 | ||
| Histologically confirmed rejection | 47 (36.7%) | ||||||
| Yes | 17 (36.2%) | 3,000 (IQR:1,500 – 477,000), range 0 to 1.45 ×108 |
3.64 ± 2.45 | p = 0.026* | 58.9 (IQR: 25.6 – 92.5), range 0.8 – 752.0 | 1.63 ± 0.67 | p = 0.735 |
| No | 30 (63.8%) | 83,400 (IQR:10,605 – 1.28 ×106), range: 0 to 2.61 ×108 | 5.02 ± 1.67 | 51.8 (IQR: 6.6 – 175.5), range 0.8 – 520.0 | 1.55 ± 0.80 |
TTVL = Torque teno virus load; QFM = QuantiFERON Monitor; *statistically significant.